

BODISEN BIOTECH, INC  
Form 8-K  
December 09, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

---

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 8, 2008

BODISEN BIOTECH, INC.  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-32616  
(Commission  
File Number)

98-0381367  
(IRS Employer  
Identification No.)

Room 2001, FanMei Building  
No. 1 Naguan Zhengjie  
Xi'an Shaanxi 710068  
Peoples Republic of China  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 86-29-87074957

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 1.01. Decision and Order received by the United States Federal Court

N/A

Item 2.01 Other Events

- (a) On December 8, 2008 the Company issued a press release announcing the results of the Town Hall Meeting held on December 2, 2008 in Alaer City, Xinjiang, China. A copy of the press release is attached hereto as Exhibit 2.01 and is incorporated herein by reference.

Exhibit No.	Description
2.01	Press release dated December 8, 2008 furnished herewith.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BODISEN BIOTECH, INC.

Date: December 8, 2008

By: /s/ Bo Chen  
Name: Bo Chen  
Title: Chairman, Chief Executive Officer and President

Exhibit Index

Exhibit No.	Description
2.01	Press release dated December 8, 2008 furnished herewith.